CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

16.57 CAD
-0.13 (-0.78%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • CPH had positive earnings in the past year.
  • CPH had a positive operating cash flow in the past year.
  • Of the past 5 years CPH 4 years were profitable.
  • Of the past 5 years CPH 4 years had a positive operating cash flow.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • CPH has a Return On Assets of 11.77%. This is amongst the best in the industry. CPH outperforms 90.91% of its industry peers.
  • CPH has a better Return On Equity (15.23%) than 87.88% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.23%, CPH belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
  • CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.53%.
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROIC 7.23%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • CPH has a Profit Margin of 34.68%. This is amongst the best in the industry. CPH outperforms 100.00% of its industry peers.
  • CPH's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CPH has declined.
  • CPH has a better Gross Margin (74.32%) than 93.94% of its industry peers.
  • CPH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CPH.CA Health Analysis

2.1 Basic Checks

  • CPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for CPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CPH has an Altman-Z score of 6.97. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of CPH (6.97) is better than 96.97% of its industry peers.
  • CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
  • CPH's Debt to FCF ratio of 0.45 is amongst the best of the industry. CPH outperforms 93.94% of its industry peers.
  • CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • CPH has a better Debt to Equity ratio (0.12) than 69.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Altman-Z 6.97
ROIC/WACC0.85
WACC8.48%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.30, CPH is doing worse than 69.70% of the companies in the same industry.
  • CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CPH's Quick ratio of 0.98 is in line compared to the rest of the industry. CPH outperforms 42.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.98
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CPH.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 126.09% over the past year.
  • CPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 43.65% yearly.
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%

3.2 Future

  • The Earnings Per Share is expected to decrease by -11.86% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 17.62% on average over the next years. This is quite good.
EPS Next Y-42.22%
EPS Next 2Y-11.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y17.62%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.59, the valuation of CPH can be described as very reasonable.
  • CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 81.82% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of CPH to the average of the S&P500 Index (25.23), we can say CPH is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 20.10, the valuation of CPH can be described as rather expensive.
  • 69.70% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (23.28), we can say CPH is valued inline with the index average.
Industry RankSector Rank
PE 11.59
Fwd PE 20.1
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • CPH's Enterprise Value to EBITDA is on the same level as the industry average.
  • Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 78.79% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.21
EV/EBITDA 15.75
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The decent profitability rating of CPH may justify a higher PE ratio.
  • CPH's earnings are expected to decrease with -11.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.27
EPS Next 2Y-11.86%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • CPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (3/20/2026, 7:00:00 PM)

16.57

-0.13 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.63%
Ins Owner ChangeN/A
Market Cap418.89M
Revenue(TTM)N/A
Net Income(TTM)17.36M
Analysts77.5
Price Target19.58 (18.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)6.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 11.59
Fwd PE 20.1
P/S 6.1
P/FCF 10.21
P/OCF 10.18
P/B 2.68
P/tB 13.37
EV/EBITDA 15.75
EPS(TTM)1.43
EY8.63%
EPS(NY)0.82
Fwd EY4.97%
FCF(TTM)1.62
FCFY9.8%
OCF(TTM)1.63
OCFY9.82%
SpS2.72
BVpS6.18
TBVpS1.24
PEG (NY)N/A
PEG (5Y)0.27
Graham Number14.1
Profitability
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROCE 10.05%
ROIC 7.23%
ROICexc 7.75%
ROICexgc 33.36%
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
FCFM 59.76%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Debt/EBITDA 0.67
Cap/Depr 1.2%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 152.24%
Profit Quality 172.34%
Current Ratio 1.3
Quick Ratio 0.98
Altman-Z 6.97
F-Score7
WACC8.48%
ROIC/WACC0.85
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-42.22%
EPS Next 2Y-11.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%
Revenue Next Year3.09%
Revenue Next 2Y17.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year143%
EBIT Next 3Y45.57%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.


What is the valuation status for CPH stock?

ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


What is the profitability of CPH stock?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.


What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 11.59 and the Price/Book (PB) ratio is 2.68.


How financially healthy is CIPHER PHARMACEUTICALS INC?

The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.